BN enrols Phase 3 study to show smallpox vaccine not weaker than its U.S. replicator

Bavarian Nordic has enrolledĀ a Phase 3 clinical study to show non-inferiority between its investigational smallpox vaccine, Imvamune and ACAM2000, the current U.S. licensed, and replicating smallpox vaccine.

This is the second and final study agreed with the U.S. Food and Drug Administration (FDA) to support the registration of liquid-frozen Imvamune. The first study, a lot consistency study in 4,000 healthy individuals, was successfully completed in 2015.

The Phase 3 non-inferiority study enrolled 440 subjects at a U.S. military garrison in South Korea led by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in collaboration with the U.S. Defense Health Agency. All subjects will have completed the study within second quarter of 2017, and top line data is anticipated in the second half of 2017.

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: “Completion of enrolment of this study represents a significant milestone in the collaboration between Bavarian Nordic, and multiple federal agencies. Imvamune has served as the cornerstone for our Company over the past decade and we will continue to work with the U.S. Government to meet their stated goal of protecting 66 million Americans who are in need of a safer smallpox vaccine. We look forward reporting these data and working with the authorities in the process towards U.S. licensure.”

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s